Minerva Neurosciences | NERV - Selling And Administration Expenses

Stock Price
6.27
Daily Change
-0.04 -0.63%
Monthly
45.14%
Yearly
219.90%
Q1 Forecast
2.46

Minerva Neurosciences reported $2.48M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Adma Biologics USD 23.05M 320K Sep/2025
ALKERMES USD 171.77M 17.9M Sep/2025
Alterity Therapeutics Limited AUD 2.29M 649.1K Jun/2023
AstraZeneca USD 4.61B 4.46B Dec/2025
BioCryst Pharmaceuticals USD 80.47M 15.39M Dec/2024
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.33M 50K Sep/2025
CSL USD 727M 453M Jun/2025
Dynavax Technologies USD 40.09M 1.45M Sep/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Grifols EUR 333.1M 157M Sep/2025
Halozyme Therapeutics USD 37.53M 4.53M Sep/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
J&J USD 6.75B 831M Dec/2025
Merck USD 2.85B 215M Dec/2025
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Neurocrine Biosciences USD 291.6M 5.3M Sep/2025
Novartis USD 3.31B 134M Sep/2025
Novavax USD 66.95M 34.05M Sep/2024
Pfizer USD 4.08B 894M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
Takeda JPY 282.78B 29.23B Dec/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024